Gross Margin % is calculated as gross profit divided by its revenue. Vita 34 AG's Gross Profit for the
three
months ended in Sep. 2023 was €8.94 Mil. Vita 34 AG's Revenue for the
three
months ended in Sep. 2023 was €20.41 Mil. Therefore, Vita 34 AG's Gross Margin % for the quarter that ended in Sep. 2023 was 43.79%.
Warning Sign:
Vita 34 AG gross margin has been in long-term decline. The average rate of decline per year is -33.3%.
The historical rank and industry rank for Vita 34 AG's Gross Margin % or its related term are showing as below:
XTER:V3V'
s Gross Margin % Range Over the Past 10 Years
Min: 3.97 Med: 56.7 Max: 59.49
Current: 14.28
During the past 13 years, the highestGross Margin % of Vita 34 AG was 59.49%. The lowest was 3.97%. And the median was 56.70%.
XTER:V3V's Gross Margin % is ranked worse than 89.98% of 609
companies
in the Healthcare Providers & Services industry
Industry Median: 41.4
vs XTER:V3V: 14.28
Vita 34 AG had a gross margin of 43.79% for the quarter that ended in Sep. 2023 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Vita 34 AG was -33.30% per year.
Vita 34 AG Gross Margin % Historical Data
The historical data trend for Vita 34 AG's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Vita 34 AG's Gross Margin %
For the Medical Care Facilities subindustry, Vita 34 AG's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita 34 AG's Gross Margin % Distribution in the Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Vita 34 AG's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Vita 34 AG's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Vita 34 AG (XTER:V3V) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Vita 34 AG had a gross margin of 43.79% for the quarter that ended in Sep. 2023 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Vita 34 AG Gross Margin % Related Terms
Thank you for viewing the detailed overview of Vita 34 AG's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Vita 34 AG is an umbilical cord blood bank. It supplies cryo-preservation and provides for the logistics to collect the blood, the preparation and the storage of stem cells from umbilical cord blood and tissue. The Group has two strategic areas that constitute the Group's reportable segments. Both segments are active in the field of stem cell banking, but differ in their organizational and operational structure with separate financial information. The products and services of the two segments correspond to the service portfolios of the two subgroups PBKM and Vita 34. It operates in Germany, Spain, and other international countries, of which maximum revenue is derived from the business operations in Germany.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XTER:V3V has been successfully added to your 